News & Analysis on Clinical Trial Services & Contract Research And Development
AMRI says it intends to expand its fill/finish capability and progress its business into higher value technology following the recent all clear at its once troubled Burlington facility.
Strategic relationships with both big pharma and mid-tier firms will drive future growth, says Charles River laboratories (CRL).
The US FDA is positioned to increase drug plant inspections in China after US President Barack Obama signed a $1.1tr (€881bn) budget for fiscal 2014 into law on Saturday.
WuXi PharmaTech has raised its 2013 financial guidance and now expects to achieve total revenues for 2013 of approximately $578m (€424m).
Aurobindo says it can make the loss making European generics operations it is buying from Actavis profitable by combining them with its production network in India.